PH3

GasDog.com Introduces New Combustible and Toxic Gas Detectors

Retrieved on: 
Wednesday, October 18, 2023
Carbon, Laboratory, NH3, HCN, PH3, C2H4, Hydrogen chloride, Sulfur dioxide, LEL, Hydrogen cyanide, ClO2, Hydrogen sulfide, CH4, Carbon monoxide, Safety, Gas, SO2, Instrumentation, Industrial gas, Oxygen, Hydrogen, Methane, Ammonia, Phosphine, Chlorine

In the latest progress, the company has announced the introduction of their latest products - Combustible Gas Detectors and Toxic Gas Detectors .

Key Points: 
  • In the latest progress, the company has announced the introduction of their latest products - Combustible Gas Detectors and Toxic Gas Detectors .
  • The newly launched detectors were developed to transform gas safety measures, providing individuals and industries with cutting-edge technology to detect and monitor gas emissions effectively.
  • GasDog's toxic gas detectors are vital tools used to monitor harmful gases in diverse environments, providing a crucial shield for lives and property against the perils of poisonous gases.
  • Portable/Handheld Detectors: GasDog handheld detectors are single gas detectors that offer reliable and accurate gases detection and monitoring for safety in various environments.

No Phosphine on Venus-According to SOFIA Observations

Retrieved on: 
Tuesday, November 29, 2022
Science, Goddard Space Flight Center, Moon, National academy, Unitary state, PH3, Engineering, Silicon, Universities Space Research Association, Telescope, University, Aircraft, Stratospheric Observatory for Infrared Astronomy, University of Stuttgart, USRA, Life, German, Government, Spectra, Ames Research Center, Phosphine, Sailor, Lightning, German Aerospace Center, DLR, Armstrong Flight Research Center, Research, SOFIA, Phosphorus, Biology, Sunlight, NASA, Light

Its observations did not find phosphine in Venus's atmosphere which is a potential biomarker and could be an indicator of organic matter, or life.

Key Points: 
  • Its observations did not find phosphine in Venus's atmosphere which is a potential biomarker and could be an indicator of organic matter, or life.
  • Venus is considered Earth's twin in many ways, but, thanks to SOFIA, the one difference now seems clearer: Unlike Earth, Venus does not have any obvious phosphine.
  • Phosphine is a gas found in Earth's atmosphere, but the announcement of phosphine discovered above Venus's clouds made headlines in 2020.
  • Despite the fact the group did not find phosphine after the stressful observations, the study was a success.

Dicerna Announces Results for PHYOX™4, Single-Dose Study of Nedosiran in Primary Hyperoxaluria Type 3 (PH3)

Retrieved on: 
Tuesday, October 19, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Back pain, Clinical trial, AES, Roche, Caregiver, Gene, PH3, Form 10-K, Metabolism, Risk, United States Census Bureau, Technology, Observation, Novo Nordisk, COVID-19, Chronic kidney disease, Primary hyperoxaluria, Lists of diseases, Patient, U.S. Securities and Exchange Commission, Tissue, Security (finance), Trial of the century, Skin, Liver, Nephrocalcinosis, LDH, NDA, Therapy, Disease, Mutation, Pain, Research, Intellectual property, Medication, RNA interference, FDA, Safety, Health, PH1, Eli Lilly, PH2, Kidney, Neurodegeneration, Heart, AE, Company, Pharmaceutical industry, Primary Hyperoxaluria (PH), Nedosiran, Dicerna Pharmaceuticals, Inc., PRIMARY HYPEROXALURIA (PH), NEDOSIRAN, DICERNA PHARMACEUTICALS, INC.

Nedosiran demonstrated safety and tolerability results in this trial consistent with previously reported studies in the PHYOX clinical development program.

Key Points: 
  • Nedosiran demonstrated safety and tolerability results in this trial consistent with previously reported studies in the PHYOX clinical development program.
  • Dicerna plans to submit an NDA to the FDA for nedosiran for the treatment of PH1 in the fourth quarter of 2021.
  • I would like to extend our sincere thanks to the patients, caregivers, investigators and their staff involved in the PHYOX4 study for their important contributions.
  • Primary hyperoxaluria (PH) is a family of ultra-rare, life-threatening genetic disorders that initially manifest with complications in the kidneys.

Dicerna Announces Data to Be Presented at American Society of Nephrology (ASN) Kidney Week 2021

Retrieved on: 
Friday, October 15, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, RNA interference, Form 10-Q, Technology, Eli Lilly, Liver, American Society of Nephrology, Primary hyperoxaluria, Heart, Lists of diseases, Gene, Pain, NDA, Chronic kidney disease, Metabolism, Tissue, Roche, PH3, SEC, Therapy, Disease, Mutation, Nephrocalcinosis, FDA, United States Census Bureau, Skin, Health, LDH, Patient, Form, Neurodegeneration, Society, ASN, Novo Nordisk, Kidney, Form 10-K, Company, PH2, EDT, Research, PH1, Medication, Pharmaceutical industry, Primary Hyperoxaluria (PH), Nedosiran, Dicerna Pharmaceuticals, Inc., PRIMARY HYPEROXALURIA (PH), NEDOSIRAN, DICERNA PHARMACEUTICALS, INC.

Given the significant unmet medical need, we believe further assessment of nedosirans potential in treating PH2 is warranted.

Key Points: 
  • Given the significant unmet medical need, we believe further assessment of nedosirans potential in treating PH2 is warranted.
  • Primary hyperoxaluria (PH) is a family of ultra-rare, life-threatening genetic disorders that initially manifest with complications in the kidneys.
  • There are three known subtypes of PH (PH1, PH2 and PH3), each resulting from a mutation in one of three different genes.
  • Excess production and accumulation of oxalate leads to recurrent kidney stones, nephrocalcinosis and chronic kidney disease that may progress to end-stage renal disease requiring intensive dialysis.